Figure 1.
Time to hematologic recovery. (A-B) Hematologic recovery for POSA-augmented cohorts F (VEN 50 mg) and H (VEN 100 mg) during induction and consolidation cycle 1: (A) days to neutrophil recovery, ≥0.5 × 109/L; and (B) days to platelet recovery, ≥50 × 109/L. (C-D) Hematologic recovery for non–POSA-augmented cohorts A to E and H during consolidation cycle 1: (C) days to neutrophil recovery, ≥0.5 × 109/L; and (D) days to platelet recovery, ≥50 × 109/L. Individual patient data are shown. Orange points indicate patients who received VEN monotherapy as consolidation. POSA, posaconazole; VEN, venetoclax.

Time to hematologic recovery. (A-B) Hematologic recovery for POSA-augmented cohorts F (VEN 50 mg) and H (VEN 100 mg) during induction and consolidation cycle 1: (A) days to neutrophil recovery, ≥0.5 × 109/L; and (B) days to platelet recovery, ≥50 × 109/L. (C-D) Hematologic recovery for non–POSA-augmented cohorts A to E and H during consolidation cycle 1: (C) days to neutrophil recovery, ≥0.5 × 109/L; and (D) days to platelet recovery, ≥50 × 109/L. Individual patient data are shown. Orange points indicate patients who received VEN monotherapy as consolidation. POSA, posaconazole; VEN, venetoclax.

Close Modal

or Create an Account

Close Modal
Close Modal